Cost–utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia by Gordois, A. et al.
Cost–utility analysis of imatinib mesilate for the treatment of
advanced stage chronic myeloid leukaemia
A Gordois1, P Scuffham*,1, E Warren2 and S Ward2
1York Health Economics Consortium Ltd, University of York, Market Square (level 2), York YO10 5NH, UK; 2School of Health and Related Research,
University of Sheff ield, Regent Court, 30 Regent Street, Sheff ield S1 4DA, UK
Imatinib mesilate (Glivecs, Novartis Pharmaceuticals) is a novel therapy for the treatment of chronic myeloid leukaemia (CML). We
evaluated the cost-effectiveness of imatinib (600 mg daily) when used for the treatment of patients in advanced stages of CML
(accelerated phase and blast crisis) against conventional therapies of combination chemotherapy (DAT) and palliative care in hospital
or at home. A Markov model simulated the transitions of hypothetical patient cohorts and outcomes were modelled for 5 years from
the start of treatment. Costs were estimated from the perspective of the UK National Health Service. Over 5 years, a patient in
accelerated phase will, on average, accrue an additional 2.09 QALYs with imatinib compared to conventional therapies, while patients
in blast crisis will accrue an additional 0.58 quality-adjusted life-years (QALYs) with imatinib compared to conventional therapies. The
costs per additional QALY gained from treatment with imatinib compared with conventional therapies were d29 344 (accelerated
phase) and d42 239 (blast crisis). The results were particularly sensitive to the price of imatinib, improvements in quality of life, and
the duration of haematological responses. We conclude that treatment of CML with imatinib confers considerably greater survival
and quality of life than conventional treatments but at a cost.
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Chronic myeloid leukaemia (CML) accounts for around 15– 20%
of all adult leukaemias (O’Brien, 2000). The incidence of CML is
1.0–1.5 new cases per 100 000 population (Kolibaba and Druker,
2000; O’Brien, 2000). In the UK, there are approximately 3000
patients with CML and 600– 800 new cases are diagnosed annually
(O’Brien, 2000). The median age at diagnosis of CML is
approximately 50 years; it is relatively uncommon in people under
the age of 20 years, and is more common among male subjects
(Bogard and Scheer, 2001).
If untreated, a patient will remain in the chronic phase of CML
for a median of 4–5 years before progressing to an acute and fatal
blast crisis phase. A transitional accelerated phase, lasting 3–9
months, is experienced by 60– 80% of patients. The median patient
survival is only 3– 6 months in blast crisis (Sawyers, 1999;
Kolibaba and Druker, 2000).
Reducing the numbers of leucocytes in the bloodstream
(haematological responses) and Philadelphia-positive (Phþ ) cells
in the bone marrow (cytogenetic responses) is the therapeutic aim.
Reductions in Phþ metaphases to less than 35% of the total
(major cytogenetic responses) have been associated with long-term
survival (The Italian Cooperative Study Group on Chronic Myeloid
Leukemia, 1994; Allan et al, 1995; Kantarjian et al, 1995). However,
therapeutic efficacy in the accelerated phase and blast crisis is
poor. Bone marrow transplantation (BMT) is the only potentially
curative therapy as conventional therapies (eg a-interferon,
hydroxyurea) do not to lead to long-term disease-free survival.
Generally, patients in advanced stages of CML receive palliative
care or experimental chemotherapy (Bogard and Scheer, 2001;
Kolibaba and Druker, 2000). However, younger patients might
receive intensive chemotherapy or BMT.
Imatinib mesilate (Glivecs, Novartis Pharmaceuticals) is an
orally administered treatment specifically targeting cancerous cells
(Druker et al, 2001a, b). Phase II trial results show relatively high
haematological and cytogenetic response rates (Kantarjian et al,
2002, Sawyers et al, 2002), even in the accelerated and blast phases
where prognosis is usually poor (Capdeville and Gathmann, 2001).
Although the duration of follow-up is currently too short to assess
long-term survival, indications suggest that imatinib offers a
considerable survival advantage over chemotherapy and palliative
care.
Imatinib’s potential benefits, improved survival and quality of
life, may be countered by increased patient management costs.
This study evaluates the cost-effectiveness of imatinib when used
in the accelerated and blast crisis phases of CML compared with
conventional therapies. Using a Markov model, we estimated the
direct costs to the UK National Health Service (NHS) of these
additional health gains.
MATERIALS AND METHODS
The analysis was undertaken for four patient cohorts: patients
presenting in accelerated phase and treated with imatinib (the
accelerated phase study cohort), patients presenting in accelerated
phase and treated with conventional therapies (the accelerated
phase comparator cohort), patients presenting in blast crisis and
treated with imatinib (the blast crisis study cohort), and patients
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presenting in blast crisis and treated with conventional therapies
(the blast crisis comparator cohort). We compared the costs and
consequences for the accelerated phase study and comparator
cohorts, and for the blast crisis study and comparator cohorts. The
total health care costs were calculated from the average patient
management costs and the number of patients in each health state.
Utility values for patient quality of life were assigned to each health
state and treatment regimen. Total quality-adjusted survival and
costs were calculated over a simulated period of 5 years.
Markov model
A Markov model was developed to simulate the transitions of a
hypothetical cohort of 1000 CML patients from the point at which
they present for treatment, through a series of health states to
death (Beck and Pauker, 1983; Sonnenberg and Beck, 1993).
Markov models are practical tools for modelling chronic diseases.
In each 1-month cycle, patient’s movement between health states is
determined by transition probabilities.
Patients are either newly diagnosed with CML in accelerated
phase or blast crisis or have previously failed conventional
treatment in chronic phase, by progressing to the advanced
disease stage. The health states in our model represent the major
clinical end points in randomised controlled trials, and correspond
to previous cost–utility analyses (Kattan et al, 1996; Liberato et al,
1997). The model is depicted in Figure 1.
Patients in the accelerated phase (ACCEL) or blast crisis
(BLAST) may respond to imatinib, having either a complete
haematological response accompanied by a major cytogenetic
response (CytR: a return to normal white blood cell (WBC) counts
and a reduction in Phþ metaphases to p35% of the total),
complete haematological response without major cytogenetic
response (CHR: a return to normal WBC counts with no major
reduction in Phþ metaphases), or partial haematological response
(PHR: the WBC count falls but is still above the normal level).
Patients remain in response states until progressing to ACCEL or
BLAST. Therefore, these responses can be considered the ‘best
response’. Unresponsive patients progress from ACCEL to BLAST
or DEATH, and from BLAST to DEATH. In all health states,
patients may die from disease-unrelated causes.
Treatments
Accelerated phase and blast crisis study cohorts receive 600 mg of
imatinib per day at home. On failing imatinib (progressing from
ACCEL to BLAST or losing their response), patients switch to
conventional therapies: combination chemotherapy or palliative
care. Combination chemotherapy (DAT) is comprised of one
course of daunorubicin, cytarabine arabinoside (Ara-C) and 6-
Tioguanine, given in hospital as an in-patient. Palliative care may
be provided at hospital or in the patient’s home. The costs for
palliative care treatments are not specified in this study because
expenditure is either absorbed within hospital bed-day costs or
incurred by the caregiver at no cost to the NHS. In the absence of
imatinib (the comparator cohorts) patients receive conventional
therapy from the outset.
The possibility that patients undergo BMT is excluded from the
analysis. Patients eligible for BMT are likely to have undergone the
procedure immediately on failure of front-line treatment (i.e., on
progressing to the accelerated phase or blast crisis from the
chronic phase). The proportion of patients newly diagnosed in the
advanced stages who undergo BMT is minimal. Additionally, it is
unclear whether BMT is indicated if the patient responds to, or is
resistant to, imatinib.
Probabilities
Transition probabilities for the accelerated phase and blast crisis
study cohorts were obtained from the international Phase II
imatinib clinical trials 0109 (237 patients presenting in accelerated
phase CML; Kantarjian et al, 2002) and 0102 (260 patients
presenting in blast crisis CML; Sawyers et al, 2002; Capdeville
and Gathmann, 2001).
Probabilities for the accelerated phase cohort were derived from
the clinical trial for patients receiving 600 mg imatinib per day (158
patients). Probabilities for the blast crisis cohort were derived from
the trial for patients who were newly diagnosed with blast crisis
and, therefore, not previously treated for that disease stage (165
patients). For accelerated-phase patients, data had not been
disaggregated by prior treatment, and for blast crisis patients,
data had not been disaggregated by imatinib daily dose. We
excluded the data on patients who were not assessable.
To calculate transition probabilities we estimated the rates of
response, disease progression and death in nonresponders, and
disease progression for those who had initially responded to
treatment but their response had waned. It was assumed that all
major cytogenetic responses accompanied a CHR (Kantarjian et al,
1995; Kattan et al, 1996; Liberato et al, 1997). The rates of CHR
(i.e., without major cytogenetic response) were estimated as the
trial rates minus the rate of major cytogenetic response. In trial
0102, the rate of major cytogenetic response exceeded the rate of
CHR. We assumed the remaining major cytogenetic responses
accompanied a PHR, and the rate of PHR was reduced accordingly
(Table 1).
All rates were converted to monthly probabilities (Beck and
Pauker, 1983; Sonnenberg and Beck, 1993). As a proportion of
patients’ progress to blast crisis without an intervening accelerated
phase, the probability for loss of response was weighted between
accelerated phase (70%) and blast crisis (30%). For the comparator
cohorts, monthly transition probabilities were calculated from the
median durations of accelerated phase and blast crisis (Kolibaba
and Druker, 2000; Reese et al, 2000). It was assumed that, on
average, DAT does not confer greater survival relative to palliative
care.
A clinician panel estimated the proportions of newly diagnosed
patients in the UK assigned to each comparator therapy (DAT,
hospital palliative care or home palliative care). The clinician panel
also estimated the proportions for accelerated phase patients
progressing to blast crisis for each treatment arm (Table 2).
Quality of life
The outcomes used in this study were quality-adjusted life-years
(QALYs). Patient’s quality of life, for each treatment and health
state, was assessed using the ‘self-reported description’ component
of the EuroQol (EQ-5D) instrument. Five dimensions are assessed
(mobility, self-care, performance of usual activities, pain/discom-
fort and anxiety/depression), each having three possible responses
(‘no problem’, ‘some difficulties/moderate problem’ or ‘unable/
CytR CHR PHR 
DEATH
ACCEL BLAST
Figure 1 Markov model process depicting movement between health
states.
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extreme problem’). Each combination of responses has an
associated utility value derived from a representative sample of
the UK public, indexed between 0 (dead) and 1 (full health); health
states with negative utilities are valued worse than death.
In the absence of utility data associated with imatinib, DAT or
palliative care, a clinician panel as used to estimate the quality of
life for an average patient in each health state and treatment
subgroup; the means of clinician responses (six respondents) were
used in the model (Table 3). Clinician-reported utilities might be
less representative of patient’s quality of life than if the scores were
obtained from a large patient sample. Therefore, subsequent
benefit and cost-effectiveness results may be underestimated or
overestimated.
QALYs were calculated for each monthly cycle as the number of
patients in each health state and treatment subgroup multiplied by
their utility values. QALYs were discounted at an annual rate of
1.5% following the NICE recommendations (National Institute for
Clinical Excellence, 2001). Discounted QALYs accrued in each
cycle were summed over the 5 years to determine the total
discounted QALYs amassed by the cohort.
Costs and resource use
Direct costs incurred by the NHS were included in the analysis
(Table 4). Consumption taxes, known in the UK as VAT, were
excluded from all costs. VAT is a transfer payment from one sector
in the economy to another, and therefore, there is no net cost or
gain to the government.
Drug costs were the averages of those listed in the British
National Formulary (2001). Imatinib’s price is d12.98 per 100 mg.
Patients receiving imatinib attend an outpatient clinic fortnightly
in accelerated phase or weekly in blast crisis. In response states,
Table 1 Model disease progression rates
Treatment From health state To health state Ratea Reference
Imatinib mesilate ACCEL CytR 28.6% (Capdeville and Gathmann, 2001)
ACCEL CHR 12.2% (Capdeville and Gathmann, 2001)
ACCEL PHR 34.0% (Capdeville and Gathmann, 2001)
ACCEL BLASTb 10.9% (Capdeville and Gathmann, 2001)
ACCEL DEATHc 22.0% (95% CI: 15.0–29.0%) (Capdeville and Gathmann, 2001)
ACCEL - CytR/CHR/PHR ACCEL or BLASTd 22.5% (95% CI: 13.6–31.5%) (Capdeville and Gathmann, 2001)
BLAST CytR 15.7% (Capdeville and Gathmann, 2001)
BLAST CHR 0.0% (Capdeville and Gathmann, 2001)
BLAST PHR 20.9% (Capdeville and Gathmann, 2001)
BLAST DEATHc 67.9% (95% CI: 56.8–79.0%) (Capdeville and Gathmann, 2001)
BLAST - CytR/CHR/PHR ACCEL or BLASTd 46.1% (95% CI: 30.9–61.3%) (Capdeville and Gathmann, 2001)
Palliative care/DAT ACCEL BLAST 50% at 6 months (Kolibaba and Druker, 2000; Reese et al, 2000)
BLAST DEATH 50% at 4.5 months (Kolibaba and Druker, 2000; Reese et al, 2000)
Disease-unrelated death Any DEATH 0.04% (Kattan et al, 1996)
aRates at 12 months, 9 months (CytR/CHR/PHR to BLAST) and 1 month (disease-unrelated death). bProgression without response (trial 0109). cOverall survival (trials 0109 and
0102). dInverse of haematological response duration rate (trials 0109 and 0102).
Table 2 Proportions of patients receiving each treatment
Accelerated Phase Blast crisis
Health states
DAT (%) Hospital
palliative
care (%)
Home
palliative
care (%) DAT (%)
Hospital
palliative
care (%)
Home
palliative
care (%)
Newly diagnosed 10 0 90 60 30 10
Chronic phase treatment failure or progression
of disease from CytR/CHR/PHR (Imatinib)
10 0 90 50 10 40
Previously treated in accelerated phase with
DAT N/A N/A N/A 30 20 50
Hospital palliative care N/A N/A N/A 50 10 40
Home palliative care N/A N/A N/A 45 21 34
Table 3 Mean (range) of utility values for health states and treatments
Health state Imatinib Combination chemotherapy Hospital palliative care Home palliative care
CytR 0.91 (0.73–1.00) N/A N/A N/A
CHR 0.91 (0.73–1.00) N/A N/A N/A
PHR 0.91 (0.73–1.00) N/A N/A N/A
ACCEL 0.58 (0.15–1.00) 0.01 (0.33 to 0.52) 0.07 (0.33 to 0.52) 0.34 (0.08 to 0.52)
BLAST 0.38 (0.02–0.69) 0.09 (0.33 to 0.52) 0.18 (0.33 to 0.02) 0.04 (0.17 to 0.20)
DEATH 0.00 0.00 0.00 0.00
NA¼ not applicable.
Cost-effectiveness of imatinib
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patients are assumed to attend, on average, once every 8 weeks
until disease progression.
For patients receiving DAT, their length of stay was assumed to
be 28 days. For patients receiving hospital palliative care, we
assumed a hospital stay of 1 month, or, for those who switched to
home palliative care or died during the monthly cycle, a hospital
stay of 0.5 months was assumed. The bed-day cost was assumed to
exclude intensive care but include palliative treatments. Patients
receiving DAT incur the cost of one course of DAT in addition to
hospital bed-day costs. Home palliative care was assumed to place
no cost on the NHS.
We assumed that patients assigned to imatinib or DAT undergo
a bone marrow test on disease progression, and patients receiving
imatinib undergo an additional bone marrow test every 6 months
(including those in response states). Palliative care patients receive
no examinations since their therapies are not aimed at response
inducement. Since data were unavailable on the cost of a bone
marrow examination, we assumed the cost was equal to that of an
outpatient appointment. Full blood counts, blood chemistry, and
physical examination are routine, low-cost tests and their cost is
absorbed within outpatient visit costs.
During blast crisis, all patients receive three chest X-rays (on
average) and 20% receive a CT scan. Patients receiving home
palliative care are not tested, but patients assigned to DAT or
hospital palliative care receive these examinations during the
inpatient period. Therefore, only the test costs themselves are
included in the analysis. During the accelerated phase or blast
crisis, patients may also receive blood transfusions. It cannot be
determined when these tests and transfusions occur, but only that,
on average, the costs are incurred during the disease stage. In our
model, these costs of tests and transfusions were attributed to the
patient in the first month of accelerated phase or blast crisis.
All patients, except hospital inpatients, receive a district nurse
home visit twice per month. Those receiving palliative care are also
visited by their GP once a month. The costs associated with these
home visits were included for all cohorts.
The total costs were estimated for all patients in each health
state, in each monthly cycle. Costs were discounted at an annual
discount rate of 6%, in line with the NICE recommendations
(National Institute for Clinical Excellence, 2001). A 5-year total
cost of treatment was then estimated for each cohort.
Incremental cost-effectiveness ratios
An incremental cost-effectiveness ratio (ICER) is calculated as the
ratio of the difference in total QALYs to the difference in total costs
between the study and comparator cohorts:
ICER ¼ ðQALYB  QALYAÞðCOSTB  COSTAÞ
ð2Þ
where QALY is the total QALYs, COST¼ total costs, A the
comparator cohort, and B¼ study cohort. The ICER is the
additional cost per additional QALY gained from treatment with
imatinib.
Sensitivity analysis
Parameters where there was the greatest uncertainty, and to which
imatinib’s cost-effectiveness was expected to be particularly
sensitive, were varied within plausible ranges (Table 5). These
parameters included the acquisition cost (price) of imatinib,
survival benefits, utility values, and the discount rates for costs and
benefits. ICERs were also estimated for best- and worst-case
Table 4 Unit costs of resources
Resource Unit cost Reference
Imatinib d90.00 per day Choice parameter
Combination chemotherapy (drugs) d575.24 per coursea The Chartered Institute of Public Finance and Accountancy (CIPFA) (2000)
and British National Formulary (2001)
Combination chemotherapy (bed days) d5068.00 per course The Chartered Institute of Public Finance and Accountancy (CIPFA) (2000)b
Hospital palliative care d181.00 per day The Chartered Institute of Public Finance and Accountancy (CIPFA) (2000)b
Blood transfusions d3242.70 per episodec National Blood Donor Registry: Leeds, UK, (Netten et al, 2002)
Outpatient clinic visit/ bone marrow test d60.00 per visit/test Department of Health (2002)d
Chest X-ray d21.00 per X-ray Personal communication (2001)e
CT scan d151.00 per scan Personal communication (2001)e
Nurse home visit d19.00 per visit Netten et al (2002)
GP home visit d45.00 per visit Netten et al (2002)
aBased on daily doses of daunorubicin (50 mg m2 for 3 days), Ara-C (100 mg m2 twice for 10 days) and 6-Tioguanine (2.5 mg kg1 for 10 days), and costs per course of
d365.66 (daunorubicin), d131.89 (Ara-C) and d77.68 (6-Tioguanine). The mean patient body surface area and weight of 1.74 m2 and 70 kg are assumed (Smithies, 1996; Gorin,
1998; Lee et al, 1998; Messori, 1998). bOther Medicine, all English Trusts. cBased on 20 U of full blood (d82.70 U1), 10 U of platelets (d151.27 U1) and 2 h nursing time
(d38.00 h1) per accelerated phase/blast crisis. dFollow-up clinical haematology outpatient attendance. ePersonal communication with six NHS Trusts (trimmed mean of
responses). Further details available from the authors on request.
Table 5 Parameters tested in the sensitivity analysis
Parameter Baseline estimate Range
Imatinib price per 100 mg d12.98 d6.49–d12.98a
12-month rate of response loss (accelerated phase study cohort) 22.5% 13.6–31.5%b
Nine-monthly rate of response loss (blast crisis study cohort) 46.1% 30.9–61.3%c
Utility of imatinib in CytR/CHR/PHR 0.91 0.73–1.00d
Utility of imatinib in ACCEL 0.58 0.15–1.00d
Utility of imatinib in BLAST 0.38 0.02–0.74d
Discount rate for QALYs 1.5% 0–6e
Discount rate for costs 6% 0–10e
aA maximum price discount of 50% might be possible in the long-term future. bBased on 95% confidence interval for 12-
month duration of haematological response (trial 0109). cBased on 95% confidence interval for 9-month duration of
haematological response (trial 0102). dRange of estimates from clinician panel. eNational Institute for Clinical Excellence,
2001.
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scenarios by setting these parameters at the most optimistic or
pessimistic limit in their range.
RESULTS
For the accelerated phase study cohort, 1-year survival and
progression-free survival rates of 80.1 and 75.0%, respectively,
were estimated from the model. These are substantially greater
than the estimates (54.8 and 24.9%) obtained for the accelerated
phase comparator cohort where patients receive DAT followed by
home palliative care (10% patients) or home palliative care only
(90% patients). From the model, we estimated median survivals of
39.5 months (study cohort) and 13.1 months (comparator cohort).
In the study cohort, the 5-year per-patient costs to the NHS were
d61 268 greater and each patient, on average, accrued 2.09
additional QALYs compared to the comparator cohort. The ICER
for the accelerated phase was d29 344 per QALY.
For the blast crisis study cohort, a 1-year survival rate of 40.4%
was estimated from the model. This is more than twice the survival
rate (15.7%) estimated for the comparator cohort where patients
receive DAT followed by home palliative care (51.4% patients),
hospital palliative care (12.9% patients), or home palliative care
only (35.7% patients). From the model, we estimated median
survivals of 8.7 months (study cohort) and 4.5 months (compara-
tor cohort). In the study cohort, the 5-year per-patient costs to the
NHS were d24 695 greater and each patient, on average, accrued
0.58 additional QALYs compared to the comparator cohort. The
ICER for blast crisis was d42 239 per QALY (Table 6).
The incremental costs and QALYs both decreased each year over
the 5 years modelled (Table 7). For initial cohorts of 1000 patients,
the average incremental cost per patient in year 5 was 38% of the
year 1 cost for patients in accelerated phase and 4.1% for patients
in blast crisis. These different annual costs reflect different survival
rates for the different stages of CML. The incremental costs per
QALY increased over time for both accelerated phase (trend ¼
d245 per month) and blast crisis (trend ¼ d65 per month).
Sensitivity analysis
Imatinib’s cost-effectiveness was sensitive to its price (Table 8).
For all discounted costs within the range, treatment with imatinib
incurred additional costs compared with conventional treatments.
If the price of imatinib was discounted by 50% (d6.49 per 100 mg),
the ICERs were 54% lower.
Since the confidence interval of 12-month haematological
response loss from imatinib in accelerated phase was narrow,
imatinib’s cost-effectiveness was insensitive to duration of
response. In blast crisis, where confidence intervals were wider,
the ICER was up to 7 higher or 8% lower.
Imatinib’s cost-effectiveness was sensitive to patient utility
values. In the accelerated phase, the ICER was up to 46% higher or
19% lower. In blast crisis, the ICER was up to 104% higher or 31%
lower. The choice of discount rates used had a relatively small
effect on the cost-effectiveness ratios.
Under a best-case scenario, the ICERs were 69% lower
(accelerated phase) and 43% lower (blast crisis). Under a worst-
case scenario, the costs per QALY were substantially greater than
at baseline (108% higher in accelerated phase; 189% higher in blast
crisis).
DISCUSSION
There have been no studies previously published which evaluate
the cost-effectiveness of treatments in the advanced stages of CML.
This may be due to the similarity in profiles between conventional
palliative therapies, inducing only temporary and/or partial
responses and rarely offering improved survival. Imatinib offers
considerable advantages over current treatments in both survival
and quality of life for the advanced stages of CML. However, the
monthly drug cost is high compared with conventional therapies
(eg low-cost home palliative care). We estimated that the marginal
cost of treatment with imatinib was d29 000 (accelerated phase)
and d42 000 (blast crisis) per QALY over a 5-year period. Imatinib
was more cost-effective in the accelerated phase due to consider-
ably better patient survival and quality of life. After 12 months of
treatment, 78% of patients in accelerated phase survived (trial
0109, 600 mg dose group) compared with 32% survival in blast
crisis (trial 0102, previously untreated group) (Capdeville and
Gathmann, 2001). Moreover, 67% of accelerated phase patients had
not experienced disease progression at 12 months.
There is uncertainty surrounding the duration of response from
imatinib during blast crisis. However, varying this parameter had
Table 6 Results of the baseline analysis (per patient)
Imatinib Comparator Incremental costs and QALYs
Accelerated phase (1000 patients)
Total discounted cost d78 593 d17 325 d61 268
Total discounted QALYs 2.04 0.04 2.09
ICER (d per additional QALY) d29 344
Blast crisis (1000 patients)
Total discounted cost d35 781 d11 085 d24 695
Total discounted QALYs 0.53 0.05 0.58
ICER (d per additional QALY) d42 239
Table 7 Annual incremental costs and QALYs (per patient)
Accelerated phase Blast crisis
Incremental Incremental Incremental Incremental
Year costs QALYs costs QALYs
1 d18 456 0.65 d13 239 0.27
2 d14 327 0.51 d4528 0.09
3 d12 084 0.40 d1601 0.02
4 d9391 0.30 d565 0.01
5 d7010 0.23 d194 0.00
Cost-effectiveness of imatinib
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little effect on imatinib’s cost-effectiveness. Using 95% confidence
intervals of response duration, the cost per QALY are up to 7%
higher (shortest duration) or 8% lower (longest duration) than the
baseline estimate. For longer responses, the increase in QALYs
outweighed the additional expense of imatinib treatment resulting
in a lower ICER.
Imatinib responders have a substantially better quality of life
than patients receiving current treatments, even under pessimistic
assumptions. The lowest estimated utility value with imatinib for
unresponsive blast crisis patients (0.02) is similar to the baseline
utility value for home palliative care (0.04) and greater than the
baseline utility value for hospital palliative care (0.18). Imatinib’s
cost-effectiveness in blast crisis varied considerably over the range
of utility values. At lower utility values, health benefits are
overshadowed by the drug price and the ICER is substantially
higher.
There are several qualifications to our model. However, our
approach to this analysis was to favour the comparator wherever
there was uncertainty. As the Phase II trials were one-arm trials it
was not possible to elicit controlled utility values from patients. In
the absence of primary patient data, we resorted to using a
clinician panel. The EQ-5D responses elicited from the clinician
panel may possibly reflect the average patient’s quality of life more
accurately than those elicited from a patient sample. We expect
clinicians to have greater experience of CML patients than an
individual with the disease. Conversely, clinicians’ ‘objective’
assessments may be no substitute for patients’ experiences.
Therefore, individual patients may convey the disease’s impact
more accurately than that perceived by clinicians. These issues
need to be addressed in future research.
We assumed that a full month of imatinib treatment was given
in each cycle. This should not substantially overstate the duration
of treatment with imatinib since there is likely to be a lag between
disease progression (treatment failure) and clinical confirmation
(cessation of treatment). As imatinib is considerably more
expensive than palliative care, this bias favours the comparator.
Patients may, in reality, move between response states (e.g., a
partial response may be attained prior to a complete response).
Owing to limitations in data availability we excluded movement
between response states representing ‘best responses’. This limits
the accuracy of our overall and progression-free survival estimates,
and may underestimate the effectiveness of imatinib.
We modelled outcomes for 5 years. The relative magnitudes of
incremental costs and benefits determine imatinib’s cost-effective-
ness over longer time horizons. Additional data on the long-term
effectiveness, changes in response, quality of life and contra-
indications of imatinib are required over the longer-term to
validate our modelled effectiveness and cost estimates. In
Table 8 Results of the sensitivity analysis (per patient)
Accelerated phase Blast crisis
Parameter/value Incremental costs Incremental QALYs ICER Incremental costs Incremental QALYs ICER
Baselinea d61 268 2.09 d29 344 d24 695 0.58 d42 239
Imatinib price per 100 mg
d6.49 (50% discount) d27 719 2.09 d13 276 d11 237 0.58 d19 220
d7.79 (40% discount) d34 439 2.09 d16 495 d13 929 0.58 d23 824
d9.09 (30% discount) d41 159 2.09 d19 713 d16 620 0.58 d28 428
d10.38 (20% discount) d47 828 2.09 d22 907 d19 312 0.58 d33 032
d11.68 (10% discount) d54 548 2.09 d25 126 d22 004 0.58 d37 636
Rates of response lossb
13.6% (response achieved from ACCEL)
30.9% (response achieved from BLAST) d69 028 2.44 d28 308 d28 212 0.73 d38 766
31.5% (response achieved from ACCEL)
61.3% (response achieved from BLAST) d54 606 1.80 d30 417 d22 293 0.49 d45 274
Imatinib utility values
0.73 (CytR/CHR/PHR)
0.15 (ACCEL)
0.02 (BLAST) d61 268 1.43 d42 958 d24 695 0.29 d85 981
1.00 (CytR/CHR/PHR)
1.00 (ACCEL)
0.74 (BLAST) d61 268 2.58 d23 717 d24 695 0.85 d28 937
Discount rates
0% (costs), 0% (QALYs) d69 528 2.15 d32 302 d26 654 0.59 d44 853
6% (costs), 0% (QALYs) d61 268 2.15 d28 465 d24 695 0.58 d41 556
6% (costs), 6% (QALYs) d61 268 1.91 d32 060 d24 695 0.56 d44 291
10% (costs), 0% (QALYs) d56 555 2.15 d26 275 d23 526 0.59 d39 589
10% (costs), 10% (QALYs) d56 555 1.77 d31 907 d23 526 0.54 d43 932
Extreme scenarios
Worst casec d61 388 1.01 d60 991 d23 838 0.20 d122 016
Best cased d27 959 3.06 d9132 d11 897 1.03 d11 556
aImatinib price per 100 mg¼ d12.98, monthly probability of response loss (response achieved from ACCEL)¼ 0.0210, monthly probability of response loss (response achieved
from BLAST) ¼ 0.0664, Imatinib utility (CytR/CHR/PHR)¼ 0.91, Imatinib utility (ACCEL)¼ 0.58, Imatinib utility (BLAST)¼ 0.38, discount rate (costs)¼ 6%, discount rate
(QALYs)¼ 1.5%. bAt 12 months (responses achieved from ACCEL) and nine months (responses achieved from BLAST). cImatinib price per 100 mg¼ d12.98, monthly
probability of response loss (response achieved from ACCEL)¼ 0.0310, monthly probability of response loss (response achieved from BLAST)¼ 0.1001, Imatinib utility
(CytR/CHR/PHR)¼ 0.73, Imatinib utility (ACCEL)¼ 0.15, Imatinib utility (BLAST)¼ 0.02, discount rate (costs)¼ 0%, discount rate (QALYs)¼ 10%. dImatinib price per
100 mg¼d6.49, monthly probability of response loss (response achieved from ACCEL)¼ 0.0121, monthly probability of response loss (response achieved from
BLAST)¼ 0.0402, Imatinib utility (CytR/CHR/PHR)¼ 1.00, Imatinib utility (ACCEL)¼ 1.00, Imatinib utility (BLAST)¼ 0.74, discount rate (costs)¼ 10%, discount rate
(QALYs)¼ 0%.
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particular, the duration of follow-up in the clinical trials as too
short to assess long-term survival. Actual 5-year survival rates with
imatinib may be substantially lower than those estimated by
assuming a constant monthly probability of death.
The effectiveness data used for this study was obtained from the
manufacturer of Imatinib (Novartis). These data are reported
elsewhere (Capdeville and Gathmann, 2001, Kantarjian et al, 2002;
Sawyers et al, 2002). In addition, these data, this cost-effectiveness
model and the results have been reviewed by the NICE. Therefore,
any potential bias from the source of funding for this study (i.e.,
Novartis) should be minimal. Moreover, we have used conservative
assumptions for any parameters where there was uncertainty; this
will bias results in favour of the comparators rather than imatinib.
The impact on NHS budgets in switching from conventional
practice to treatment with imatinib for patients in the advanced
stages of CML is a major policy consideration. Assuming 70% of
advanced stage CML patients are in accelerated phase and 30% in
blast crisis, the costs per patient for treatment with imatinib in
years 1 and 5 were d17 300 and d5100, respectively. For an
estimated 1000 advanced stage CML patients in the UK, the
average cost to each of the 28 new strategic health authorities
(StHAs) will be approximately d0.6 m per year. This cost will have
a relatively small impact on the budgets of StHAs; and given that
the alternative treatments for CML are considerably less effective,
imatinib mesilate is the logical and economically feasible treatment
for those with advanced stages of CML.
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